DF
MCID: DNG005
MIFTS: 59

Dengue Virus (DF)

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 56
Dengue Fever, Protection Against 56 13 6
Dengue Virus, Susceptibility to 56 29 39
Dengue Fever 58 3 71
Df 58 3
Dengue Virus Infection 58

Characteristics:

Orphanet epidemiological data:

58
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Dengue Virus

OMIM : 56 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to encephalitis and zika fever, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and endothelial, and related phenotypes are fever and headache

CDC : 3 Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world's population, about 3 billion people, live in areas with a risk of dengue. Dengue is often a leading cause of illness in areas with risk.

Wikipedia : 74 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne, single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.0 RSAD2 RPSA DDX58 CD209
2 zika fever 31.0 STAT2 CD209
3 viral infectious disease 30.7 STAT2 IFIH1 DDX58 CD209
4 chikungunya 30.6 SHFL RSAD2 OAS3 DDX58 CD209
5 west nile virus 30.3 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 EXOC1
6 severe acute respiratory syndrome 30.2 IFIH1 DDX58 CD209
7 tick-borne encephalitis 30.1 RSAD2 OAS3 DDX58 CD209
8 west nile fever 30.1 OAS3 CD209
9 measles 30.0 STAT2 IFIH1 DDX58 CD209
10 stomatitis 29.8 RSAD2 IFITM3 IFITM2 DDX58
11 rift valley fever 29.8 IFITM3 IFITM2 IFITM1 CD209
12 herpangina 29.7 STAT2 IFIH1 DDX58
13 lassa fever 29.7 IFITM3 IFIH1 DDX58 CD209
14 hepatitis c virus 29.4 RSAD2 IFITM3 IFITM1 DDX58 CLDN1
15 influenza 28.7 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 DDX58
16 hepatitis 28.6 RSAD2 MRC1 IFIH1 HAVCR1 DDX58 CLDN1
17 dengue disease 12.5
18 dengue shock syndrome 11.9
19 dengue hemorrhagic fever 11.9
20 asymptomatic dengue 11.8
21 yellow fever 10.8
22 japanese encephalitis 10.8
23 thrombocytopenia 10.7
24 exanthem 10.6
25 cytokine deficiency 10.6
26 vaccinia 10.5
27 microcephaly 10.4
28 severe combined immunodeficiency 10.4
29 neutropenia 10.4
30 guillain-barre syndrome 10.4
31 appendicitis 10.3
32 hemorrhagic disease 10.3
33 st. louis encephalitis 10.3
34 48,xyyy 10.3
35 form agnosia 10.3
36 agnosia 10.3
37 acute pancreatitis 10.3
38 myelitis 10.3
39 viral hemorrhagic fever 10.3
40 viral hepatitis 10.2
41 myositis 10.2
42 singleton-merten syndrome 10.2 IFIH1 DDX58
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
44 viral encephalitis 10.2
45 neuroblastoma 10.2
46 encephalopathy 10.2
47 acute liver failure 10.2
48 kawasaki disease 10.2
49 acute kidney tubular necrosis 10.2
50 uveitis 10.2

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Human phenotypes related to Dengue Virus:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
4 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
5 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
6 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
7 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
8 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
9 gingival bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0000225
10 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
11 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
12 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
13 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
14 petechiae 58 31 occasional (7.5%) Occasional (29-5%) HP:0000967
15 bruising susceptibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000978
16 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
17 cerebral hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0001342
18 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
19 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
20 leukopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001882
21 hypoproteinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003075
22 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543

Clinical features from OMIM:

614371

UMLS symptoms related to Dengue Virus:


fever, pruritus

GenomeRNAi Phenotypes related to Dengue Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.47 RPSA
2 Decreased viability GR00221-A-2 9.47 NRBP1
3 Decreased viability GR00221-A-3 9.47 NRBP1
4 Decreased viability GR00240-S-1 9.47 RPSA
5 Decreased viability GR00249-S 9.47 IFITM1 LGALS9 RPSA
6 Decreased viability GR00381-A-1 9.47 IFITM1 RPSA
7 Decreased viability GR00386-A-1 9.47 STAT2
8 Decreased viability GR00402-S-2 9.47 LGALS9 NRBP1 RPSA SHFL

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Anti-Allergic Agents Phase 4
4 Histamine Antagonists Phase 4
5 Histamine H1 Antagonists Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Neurotransmitter Agents Phase 4
8
tannic acid Approved Phase 3 1401-55-4
9
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
10
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
11
Hydroxychloroquine Approved Phase 3 118-42-3 3652
12
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
13 Immunologic Factors Phase 3
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
15 Antirheumatic Agents Phase 3
16 Antiparasitic Agents Phase 3
17 Anti-Infective Agents Phase 3
18 Antiprotozoal Agents Phase 3
19 Anti-Bacterial Agents Phase 3
20 Antimalarials Phase 3
21 Antioxidants Phase 3
22 Protective Agents Phase 3
23 silymarin Phase 3
24
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
25
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
26
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
27 Pharmaceutical Solutions Phase 2
28 Rho(D) Immune Globulin Phase 2
29 Immunoglobulins, Intravenous Phase 2
30 gamma-Globulins Phase 2
31 Plasma-lyte 148 Phase 2
32 Vaccines Phase 2
33 Immunoglobulins Phase 2
34 Antibodies Phase 2
35 Dermatologic Agents Phase 2
36 Antibodies, Blocking Phase 2
37 Keratolytic Agents Phase 2
38
Aluminum sulfate Approved Phase 1 10043-01-3
39
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
40
Varespladib methyl Investigational Phase 1 172733-08-3
41 Antacids Phase 1
42 Adjuvants, Immunologic Phase 1
43 Anti-Ulcer Agents Phase 1
44 Gastrointestinal Agents Phase 1
45
Albendazole Approved, Vet_approved 54965-21-8 2082
46
Mebendazole Approved, Vet_approved 31431-39-7 4030
47
Caffeine Approved 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
3 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
4 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
5 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
6 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Completed NCT02992418 Phase 3
8 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
9 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
10 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03771963 Phase 3
11 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
12 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
13 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
14 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
15 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Recruiting NCT03999996 Phase 3
16 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial Recruiting NCT04391127 Phase 3 Hydroxychloroquine;Ivermectin;Placebo
17 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old Active, not recruiting NCT02747927 Phase 3 TDV Placebo
18 A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue Not yet recruiting NCT04313244 Phase 3
19 Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study Not yet recruiting NCT04371952 Phase 3 Doxycycline;Placebo
20 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
21 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
22 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
23 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
24 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
25 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
26 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
27 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
28 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
29 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
30 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
31 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
32 A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore Completed NCT02425098 Phase 2
33 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
34 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
35 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
36 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
37 A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US Completed NCT02421367 Phase 1, Phase 2
38 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
39 A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
40 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America Completed NCT02302066 Phase 2
41 Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of Two Doses of the LID/NIAID Live-Attenuated Tetravalent Dengue Vaccine, TV003, Administered Six Months Apart, to Healthy Adults, Adolescents, and Children in Thailand Completed NCT02332733 Phase 2
42 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
43 A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
44 A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 ("A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series Completed NCT01843621 Phase 1, Phase 2
45 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
46 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
47 Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan Recruiting NCT04133987 Phase 2
48 Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
49 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Active, not recruiting NCT02628444 Phase 2
50 An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults Active, not recruiting NCT03746015 Phase 2

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 29 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

40
Testes, T Cells, Endothelial, Liver, Monocytes, B Cells, Skin

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 9097)
# Title Authors PMID Year
1
A variant in the CD209 promoter is associated with severity of dengue disease. 61 56 6
15838506 2005
2
IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. 56 61
28126818 2017
3
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. 61 56
26138103 2015
4
Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. 56 61
25939314 2015
5
A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies. 56 61
21107723 2011
6
Dengue: a continuing global threat. 56 61
21079655 2010
7
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. 61 56
20855599 2010
8
Discovery of insect and human dengue virus host factors. 61 56
19396146 2009
9
CLEC5A is critical for dengue-virus-induced lethal disease. 61 56
18496526 2008
10
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. 61 56
12783086 2003
11
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. 56
22001756 2011
12
The pathogenesis of dengue. 56
21781999 2011
13
Dengue hemorrhagic fever is associated with polymorphisms in JAK1. 56
20588308 2010
14
Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. 6
16379498 2006
15
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 6
15564514 2004
16
A generalized within-host model of dengue infection with a non-constant monocyte production rate. 61
32122254 2020
17
CRISPR-based platform for carbapenemases and emerging viruses detection using Cas12a (Cpf1) effector nuclease. 61
32486913 2020
18
A Study of the Effects of pH and Surfactant Addition on Gold Nanoparticle Aggregation. 61
32331118 2020
19
Nucleotide-dependent dynamics of the Dengue NS3 helicase. 61
32371149 2020
20
Anti-flavivirus activity of polyoxometalate. 61
32376449 2020
21
The old pharmaceutical oleoresin labdanum of Cistus creticus L. exerts pronounced in vitro anti-dengue virus activity. 61
31669444 2020
22
Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication. 61
32141690 2020
23
Nicking-assisted on-loop and off-loop enzymatic cascade amplification for optomagnetic detection of a highly conserved dengue virus sequence. 61
32339155 2020
24
Laboratory-Acquired Dengue Virus Infection, United States, 2018. 61
32568040 2020
25
Multiple dengue virus serotypes resistant transgenic Aedes aegypti fitness evaluated under laboratory conditions. 61
32138589 2020
26
Comprehensive treatment in severe dengue during preterm and term labor: could tocolysis be useful? 61
30626246 2020
27
The association of obesity and severe dengue: possible pathophysiological mechanisms. 61
32413364 2020
28
Microsatellite typing of Aedes albopictus (Diptera: Culicidae) populations from Germany suggests regular introductions. 61
32045712 2020
29
Identification of potential inhibitors for targets involved in Dengue fever. 61
32552652 2020
30
Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. 61
32579258 2020
31
Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism. 61
32442424 2020
32
Impact of dengue-preventive behaviors on Aedes immature production in Bang Kachao, Samut Prakan Province, Thailand: a cross-sectional study. 61
32527239 2020
33
Roles of Macrophage Migration Inhibitory Factor in Dengue Pathogenesis: From Pathogenic Factor to Therapeutic Target. 61
32545679 2020
34
A Phase 1, Open Label- Assessment of a Dengue Virus-1 Live Virus Human Challenge - (DENV-1-LVHC) Strain. 61
32572470 2020
35
Rapid visual detection of dengue virus by combining reverse transcription recombinase-aided amplification with lateral-flow dipstick assay. 61
32272263 2020
36
Mobile Laboratory Reveals the Circulation of Dengue Virus Serotype I of Asian Origin in Medina Gounass (Guediawaye), Senegal. 61
32560073 2020
37
Voltammetric sensing of recombinant viral dengue virus 2 NS1 based on Au nanoparticle-decorated multiwalled carbon nanotube composites. 61
32488309 2020
38
A quantitative luciferase-based cell-cell fusion assay to measure four-serotype dengue virus E protein-triggered membrane fusion. 61
32530355 2020
39
A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies. 61
32532141 2020
40
Characterization of the type-specific and cross-reactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine. 61
32572472 2020
41
Combinatorial resurfacing of Dengue envelope protein domain III antigens selectively ablates epitopes associated with serotype-specific or infection-enhancing antibody responses. 61
32574486 2020
42
Determining the association between dengue and social inequality factors in north-eastern Brazil: A spatial modelling. 61
32575962 2020
43
DNA-induced 2'3'-cGAMP enhances haplotype-specific human STING cleavage by dengue protease. 61
32576686 2020
44
The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin. 61
32559771 2020
45
Generative Adversarial Networks (GANs) Based Synthetic Sampling for Predictive Modeling. 61
32558335 2020
46
Within-Host Viral Diversity: A Window into Viral Evolution. 61
32511081 2020
47
Sylvatic Mosquito Diversity in Kenya-Considering Enzootic Ecology of Arboviruses in an Era of Deforestation. 61
32503123 2020
48
Evaluation of ViroTrack Sero Zika IgG/IgM, a New Rapid and Quantitative Zika Serological Diagnostic Assay. 61
32512812 2020
49
Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo. 61
32517029 2020
50
Analysis of cell-associated DENV RNA by oligo(dT) primed 5' capture scRNAseq. 61
32493997 2020

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CD209 CD209, -336A-GSNV protective,risk factor 5408

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.83 RSAD2 RPSA OAS3 NRBP1 MRC1 IFITM3
2 plasma membrane GO:0005886 9.44 STAT2 RPSA OAS3 MRC1 IFITM3 IFITM2

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.1 RSAD2 OAS3 IFITM3 IFITM2 IFITM1 IFIH1
2 immune system process GO:0002376 10.06 RSAD2 OAS3 LGALS9 IFITM3 IFITM2 IFITM1
3 viral entry into host cell GO:0046718 9.91 RPSA MRC1 HAVCR1 CLEC5A CLDN1 CD209
4 response to virus GO:0009615 9.91 RSAD2 OAS3 IFITM3 IFITM2 IFITM1 IFIH1
5 viral process GO:0016032 9.9 STAT2 RSAD2 RPSA MRC1 IFIH1 HAVCR1
6 cellular response to interferon-gamma GO:0071346 9.78 MRC1 LGALS9 CLDN1
7 response to interferon-gamma GO:0034341 9.78 SHFL IFITM3 IFITM2 IFITM1
8 response to interferon-beta GO:0035456 9.76 SHFL IFITM3 IFITM2 IFITM1
9 positive regulation of interleukin-6 secretion GO:2000778 9.73 LGALS9 IFIH1 DDX58
10 negative regulation of viral genome replication GO:0045071 9.73 SHFL RSAD2 OAS3 IFITM3 IFITM2 IFITM1
11 positive regulation of tumor necrosis factor secretion GO:1904469 9.7 LGALS9 IFIH1 DDX58
12 negative regulation of viral entry into host cell GO:0046597 9.69 IFITM3 IFITM2 IFITM1
13 response to interferon-alpha GO:0035455 9.67 IFITM3 IFITM2 IFITM1
14 negative regulation of type I interferon production GO:0032480 9.63 IFIH1 DDX58
15 cellular response to virus GO:0098586 9.62 LGALS9 IFI6
16 positive regulation of interferon-beta production GO:0032728 9.62 IFIH1 DDX58
17 cellular response to exogenous dsRNA GO:0071360 9.61 IFIH1 DDX58
18 positive regulation of interferon-alpha production GO:0032727 9.6 IFIH1 DDX58
19 positive regulation of interferon-alpha secretion GO:1902741 9.59 IFIH1 DDX58
20 positive regulation of response to cytokine stimulus GO:0060760 9.58 IFIH1 DDX58
21 detection of virus GO:0009597 9.58 IFIH1 DDX58
22 positive regulation of interferon-beta secretion GO:0035549 9.57 IFIH1 DDX58
23 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.55 IFIH1 DDX58
24 regulation of type III interferon production GO:0034344 9.54 IFIH1 DDX58
25 type I interferon signaling pathway GO:0060337 9.5 STAT2 RSAD2 OAS3 IFITM3 IFITM2 IFITM1
26 defense response to virus GO:0051607 9.36 STAT2 SHFL RSAD2 OAS3 IFITM3 IFITM2

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 OAS3 IFIH1 DDX58
2 mannose binding GO:0005537 9.26 MRC1 CD209
3 carbohydrate binding GO:0030246 9.26 MRC1 LGALS9 CLEC5A CD209
4 virus receptor activity GO:0001618 9.1 RPSA MRC1 HAVCR1 CLEC5A CLDN1 CD209

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....